Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2024-04-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 5th Board of Directors of the company, including approval of the 2023 Annual Report, 2023 Annual Financial Statements, audit reports, profit distribution proposals, remuneration plans, stock repurchase plans, amendments to the Articles of Association, and the scheduling of the 2023 Annual General Meeting. It also mentions the approval of the 2024 Q1 report. The document is a formal board meeting resolution announcement, not the actual annual report or financial statements themselves. It references that the full reports are disclosed separately on the official disclosure website (cninfo.com.cn). The document is about board/management decisions and approvals, including management reports and audit committee reviews, but does not contain the full financial data or the full annual report itself. Therefore, it fits best under the category of Board/Management Information (MANG).
2024-04-25 Chinese
《公司章程》修正案
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding amendments to the company's Articles of Association (公司章程). It details changes in the registered capital and share capital due to the cancellation of restricted shares. The document mentions that the amendment requires shareholder approval at a general meeting. The content focuses on corporate governance and capital structure changes but does not contain financial statements or detailed financial performance data. The document length is short (795 characters), and it is an announcement of changes rather than a full report. This fits best under Share Issue/Capital Change (SHA) as it relates to changes in share capital and company articles reflecting that change.
2024-04-25 Chinese
国浩律师（深圳）事务所关于公司2021年限制性股票激励计划回购注销部分限制性股票相关事项之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted shares under a 2021 restricted stock incentive plan of a company. It details the approval process, legal compliance, and specifics of the stock repurchase and cancellation. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a corporate action involving share repurchase and cancellation. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal compliance and disclosure document related to corporate governance and share repurchase, not a standalone audit report or capital/financing update. The document length and content confirm it is not merely an announcement but a detailed legal opinion. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-04-25 Chinese
关于召开2023年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of 健帆生物科技集团股份有限公司. It includes information about the meeting date, voting procedures, proposals to be voted on (including the 2023 Annual Report, Board and Supervisory reports, financial statements, profit distribution plan, remuneration plans, audit fees, stock repurchase, and amendments to the company charter), and instructions for shareholders to register and vote either in person or online. The document is primarily an announcement and invitation to the AGM, not the actual annual report or financial statements themselves. It contains procedural details and voting instructions rather than substantive financial data or management discussion. Therefore, it fits the category of AGM Information (AGM-R). The document length is over 5,000 characters and contains detailed meeting information, supporting this classification with high confidence.
2024-04-25 Chinese
中航证券有限公司关于公司2023年度募集资金存放与实际使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a sponsoring institution (中航证券有限公司) regarding the 2023 annual verification of the storage and actual use of funds raised by 健帆生物科技集团股份有限公司 through convertible bonds. It includes specifics on the amount raised, usage of funds, management of funds, compliance with regulatory requirements, and an auditor's verification opinion. The document is focused on the use and management of raised capital, not a general annual report or earnings release. It is not a brief announcement but a substantive report with financial figures and compliance details. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (5533 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2024-04-25 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the external audit firm for the fiscal year 2023. It discusses the audit firm's qualifications, the audit process, communication with management, and the issuance of the audit report for the 2023 annual financial statements. The document includes detailed information about the audit procedures and the committee's oversight role, indicating it is a standalone audit report or audit information document rather than the full annual report itself. The document length is 2312 characters, which is relatively short but contains substantive content about the audit firm's performance and the audit process, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2023
2024-04-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.